Donald C. Fresne

Epigen, Inc. develops products to monitor, diagnose and treat cancer n a more effective, less expensive and less invasive manner than other products currently available. The company is in the process of completing the development of its in-vitro blood test, a confirmatory test for prostate cancer. This employs the use of the HC Antigen. It was founded on April 24, 1991.

Epigen, Inc. develops products to monitor, diagnose and treat cancer n a more effective, less expensive and less invasive manner than other products currently available. The company is in the process of completing the development of its in-vitro blood test, a confirmatory test for prostate cancer. This employs the use of the HC Antigen. It was founded on April 24, 1991.

Epigen, Inc. develops products to monitor, diagnose and treat cancer n a more effective, less expensive and less invasive manner than other products currently available. The company is in the process of completing the development of its in-vitro blood test, a confirmatory test for prostate cancer. This employs the use of the HC Antigen. It was founded on April 24, 1991.

Epigen, Inc. develops products to monitor, diagnose and treat cancer n a more effective, less expensive and less invasive manner than other products currently available. The company is in the process of completing the development of its in-vitro blood test, a confirmatory test for prostate cancer. This employs the use of the HC Antigen. It was founded on April 24, 1991.

Epigen, Inc. develops products to monitor, diagnose and treat cancer n a more effective, less expensive and less invasive manner than other products currently available. The company is in the process of completing the development of its in-vitro blood test, a confirmatory test for prostate cancer. This employs the use of the HC Antigen. It was founded on April 24, 1991.